Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$321.91 USD

321.91
2,654,799

+0.12 (0.04%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor

by Zacks Equity Research

BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.

The Zacks Analyst Blog Highlights Amgen, Altria Group, Uber Technologies, Microchip Technology, and Arista Networks

by Zacks Equity Research

Amgen, Altria Group, Uber Technologies, Microchip Technology, and Arista Networks are part of Zacks top Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Amgen, Altria Group & Uber

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), Altria Group, Inc. (MO), and Uber Technologies, Inc. (UBER).

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to These Q1 Earnings Releases?

by Sweta Jaiswal, FRM

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Radius (RDUS) Q1 Loss Wider Than Expected, Revenues Decline

by Zacks Equity Research

Radius (RDUS) posts a y/y wider Q1 loss and misses revenue estimates.

Ligand (LGND) Q1 Earnings Beat, OmniAb Spin-Off on Track

by Zacks Equity Research

Ligand (LGND) reports encouraging first-quarter 2022 numbers by beating estimates on both counts. However, Captisol sales get hurt by lower demand for COVID-19 therapies.

Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News

by Zacks Equity Research

Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Pfizer (PFE) Q1 Earnings & Sales Miss Estimates, Stock Down

by Zacks Equity Research

Pfizer (PFE) misses estimates for Q1 earnings and sales. It did not raise its sales guidance for 2022. Stock declines.

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHD

AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica

by Zacks Equity Research

AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares decline.

Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute

by Zacks Equity Research

Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.

Amgen (AMGN) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 0.71% and 2.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kanishka Das headshot

Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More

by Kanishka Das

Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.

Sweta Killa headshot

Healthcare ETFs in Focus Ahead of Q1 Earnings

by Sweta Killa

The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.

The Zacks Analyst Blog Highlights Amgen, Chevron, Coca-Cola, Visa and Merck

by Zacks Equity Research

Amgen, Chevron, Coca-Cola, Visa and Merck have been included in this Analyst Blog.

Gilead (GILD) to Report Q1 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) first-quarter 2022 results.

Why Amgen (AMGN) Might Surprise This Earnings Season

by Zacks Equity Research

Amgen (AMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Nalak Das headshot

5 Blue-Chip Stocks Likely to Gain on Earnings Results This Week

by Nalak Das

Five Dow stocks with positive Earnings ESP will report earnings results this week. These are: V, Ko, MRK, CVX and AMGN.

Is a Beat Likely for Amgen (AMGN) This Earnings Season?

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others and the biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Amgen (AMGN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed at $255.46 in the latest trading session, marking a +0.03% move from the prior day.

Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Glaxo's (GSK) NDA for Daprodustat Gets Accepted by the FDA

by Zacks Equity Research

Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.